A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects with Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination with Pembrolizumab in Subjects with Advanced Gastrointestinal Tumors.
ENROLLING
Trial ID:
NCT02675946 Protocol # :
17-489
Conditions
Solid Tumors
GI Cancer
Phase
I
Disease Sites
Lip, Oral Cavity and Pharynx
Esophagus
Stomach
Small Intestine
Colon
Rectum
Anus
Liver
Pancreas
Other Digestive Organ
Larynx
Lung
Other Respiratory and Intrathoracic Organs
Bones and Joints
Soft Tissue
Mycosis Fungoides
Other Skin
Breast
Cervix
Corpus Uteri
Ovary
Other Female Genital
Prostate
Other Male Genital
Urinary Bladder
Kidney
Other Urinary
Eye and Orbit
Brain and Nervous System
Thyroid
Unknown Sites
Ill-Defined Sites
Other Endocrine System
Kaposi's Sarcoma
Melanoma, Skin
Principal Investigator
GIANNAKIS, MARIOS
Site Investigator
Parikh, Aparna, Raj
Zhu, Andrew, X.
Site Research Nurses
Connelly, Alexandra
Creedon, Siobhan
Delrosso, Alexandria, P.
Furtado, Mollie, E.
Germon, Victoria
Graham, Christopher
Gribbin, Nicola
Johnston, Joanna, L.
Leisner, Claire
Livengood, Amanda
Lynch, Patricia
Newbert, Gordon, E.
Ritterband, Lauren
Sawin, Mark
Trial Description
Call 877-DF-TRIAL (877-338-7425) to learn more about this clinical trial, protocol #17-489
17-489